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ABSTRACT 
DNA methylation is one of the well-known epigenetic modifications. 
Aberrant DNA methylation has been shown to have a major role in 
tumorigenesis and is associated with tumor aggressiveness and inferior 
outcome in various cancer types. Chronic lymphocytic leukemia (CLL) is the 
most common adult leukemia characterized by the accumulation and clonal 
expansion of long-lived neoplastic B-lymphocytes. It is clinically and 
biologically a very heterogeneous disease. The specific aim of study I is to 
investigate the role of the tumor suppressor gene, Microcephalin (MCPH1) in 
regulating the expression of the Angiopoietin gene (ANGPT2) in CLL. We 
showed that MCPH1 negatively regulates ANGPT2 gene, which is 
overlapping with MCPH1 in opposite direction through a novel mechanism.  
MCPH1 physically binds to the ANGPT2 promoter and recruits the DNA 
methylation machinery for subsequent silencing of ANGPT2. Study II is 
mainly focused on epigenetic silencing of miR26A1 microRNA and its 
impact on Enhancer of zeste homolog 2 (EZH2) in CLL and mantle cell 
lymphoma (MCL). We showed that miR26A1 acts as a tumor suppressor and 
epigenetically silenced in CLL, which is required for maintaining high levels 
of EZH2, resulting in poor overall survival. Finally, in study III we analyzed 
the mechanisms behind Ten-eleven-translocation 1 (TET1) deregulation in 
CLL. Here we characterized mechanisms that control TET1 gene activity at 
the transcriptional level.  Overall, we proposed a model by which the TET1 
gene activation in CLL depends on miR26A1 regulated EZH2 binding at the 
TET1 promoter and silencing of a novel cryptic promoter through gene-body 
 hypermethylation. In conclusion, these three studies deepen our knowledge in 
understanding the functional role of DNA methylation controlled tumor-
related genes in CLL, resulting in the identification of potential prognostic 
biomarkers and target for therapy. 
Keywords: DNA methylation, epigenetic modifications, CLL, MCPH1, 
ANGPT2, EZH2, miR26A1, TET1, MCL, tumor suppressor, gene-body, 
expression, prognostic biomarkers  
 
SAMMANFATTNING PÅ SVENSKA 
Metylering är en av de mest välkända epigenetiska modifieringarna av DNA. 
Avvikelser i metyleringsmönstret har visats ha en viktig roll vid malign 
transformation och är associerad med försämrad prognos vid flera olika 
cancersjukdomar. Kronisk lymfatisk leukemi (KLL) är den vanligaste 
leukemiformen hos vuxna och karaktäriseras av ansamling och klonal 
expansion av neoplastiska B lymfocyter. Sjukdomen är både kliniskt och 
biologiskt heterogen. I artikel 1 var syftet att undersöka vilken roll 
tumörsuppressorgenen Microcephalin (MCPH1) har i transkriptionell 
reglering av genen Angiopoietin (ANGPT2) vid KLL. Vi visar att MCPH1 
hämmar transkription av ANGPT2, som sker överlappande med MCPH1 fast 
i motsatt riktning. Detta sker genom att MCPH1 fysiskt binder till promotorn 
till ANGPT2 och därefter rekryterar metyltransferas som deltar i DNA-
metylering av promotorn, vilket hämmar transkription av ANGPT2. Artikel 2 
har sitt fokus på epigenetisk nedreglering (epigenetic silencing) av miR26A1 
och dess effekt på Enhancer of zeste homolog 2 (EZH2) vid KLL och 
mantelcellslymfom (MCL). Vi visar att miR26A1fungerar som en 
tumörsuppressor, då epigenetisk nedreglering av miR26A1 leder till förhöjda 
nivåer av EZH2 och försämrad prognos vid KLL. Slutligen utreder vi i artikel 
3 mekanismerna bakom dysreglering av Ten-eleven-translocation 1 (TET1) 
vid KLL. Här karaktäriseras mekanismer som är inblandade i transkription av 
genen TET1. Vi lägger fram en modell i vilken aktivering av TET1 vid KLL 
beror av miR26A1 reglerad inbindning av EZH2 till promotorn till TET1. 
Denna inbindning hämmar expression, genom hypermetylering av genens 
introniska regioner, en tidigare okänd kryptisk promotor för ett transkript i 
motsatt riktning. Sammanfattningsvis har dessa studier bidragit till fördjupad 
förståelse för betydelsen av DNA-metylering av gener inblandade i 
utveckling av KLL, vilka har potential att användas som prognostiska 
biomarkörer eller för riktad behandling. 
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1 INTRODUCTION 
1.1  Epigenetics and its modifications 
The human body consists of more than 200 types of cells. Each cell type 
maintains a unique cellular identity represented by the particular 
transcriptional program. There must be strict regulation of gene expression in 
each cell within the human body as the genetic material is essentially 
identical in almost all the cell types in the body. Transcriptional regulation is 
carried out by controlling the accessibility to genes which is achieved by the 
packaging of DNA into particular arrangements. The DNA contains the 
genetic information encoded by the sequential order of four nucleotides: 
adenine (A), guanine (G), thymidine (T) and cytosine (C).  DNA is wrapped 
around proteins called histones, which are structurally organized and 
condensed into chromatin.  Chromatin is a complex dynamic structure of 
DNA, proteins (histones) and RNA. Histone proteins can be modified and 
these modifications serve as important regulators in the transcription of 
necessary genes throughout the life cycle of an organism.  
‘’Epigenetics’’ term was coined by Conrad Hal Waddington in 1942 and 
defined as “the branch of biology which studies the causal interactions 
between genes and their products which bring the phenotype into being’’1 
and recently it is defined as “the mitotically and /or meiotically stable 
heritable changes in gene expression that are caused by mechanisms other 
than alterations in the genetic sequence”2.  Waddington explained the cellular 
levels of differentiation arising from common progenitors culminating in a 
fully formed organism. Epigenetic changes refer to “somatically heritable 
modifications to the genome that do not involve changes in the nucleotide 
sequence that leads to altered gene expression’’.  In fact, all cells of a 
complex multicellular organism contain the same genetic information, but 
during development, each single cell differentiates into a specific phenotype 
and remembers the genetic information without any changes in DNA 
sequence. This feature of epigenetics implies that the accuracy of epigenetic 
modifications is vital for maintaining the genome integrity and the cell 
phenotype. Abnormal regulation in epigenetic mechanisms tends to induce 
various complex diseases including cancer, neurodegenerative disorders, 
obesity, cardiovascular diseases etc., Indeed, epigenetics contributes to the 
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understanding of mechanisms underlying different diseases for which genetic 
mutations are not the only cause. Epigenetic modifications are essential for 
normal development and the maintenance of gene expression patterns in 
mammalian cells. Failure to maintain heritable epigenetic marks results in 
inappropriate activation or inhibition of signaling pathways, leading to 
certain specific disorders. Epigenetic modifications are dependent on changes 
in chromatin structure which defines how genetic information is organized 
within a cell3. DNA methylation, histone modifications, nucleosome 
remodeling, and non-coding regulatory RNAs (including microRNAs) are the 
examples of such modifications4. Interaction and co-operation between these 
different modifications regulate the accessibility and compaction of 
chromatin, resulting in modulating gene expression. This thesis mainly 
addresses the epigenetic pattern at the level of DNA methylation in chronic 
lymphocytic leukemia (CLL) along with the implication of chromatin 
modifier which is Enhancer of zeste homologue 2 (EZH2) in addition to non-
coding RNAs and how such epigenetic pattern in CLL regulates oncogenes 
and tumor suppressors.  
 
1.1.1  DNA methylation   
Methylation of DNA occurs at the 5’-carbon of a cytosine (5mC), commonly 
when preceding guanine (CpG) (Figure 1). In mammals, cytosine 
methylation is primarily restricted to the symmetrical CpG context. DNA 
methylation mainly targets CpGs that can be clustered in CpG rich regions 
(CpG islands), be scattered in regions with less condensed CpGs around the 
CpG islands (CpG shores) or be found as individual CpGs. Methylation of 
the fifth position of cytosine is the best studied and mechanistically 
understood epigenetic modifications and is well conserved among most plant, 
fungal and animal models. Three evolutionary conserved enzymes, DNA 
methyltransferase 1 (DNMT1), DNMT3A and DNMT3B are responsible for 
its deposition, maintenance and are essential for normal development5,6. The 
interconnection between DNA methylation and other epigenetic 
modifications such as histone modifications results in strong functional 
effects on regulating gene expression. DNA methylation marks are 
established during embryonic development and are copied to the following 
generation through DNA replication. Interestingly, due to the environmental 
factors such as nutrition, exercise, metabolites, exercise, chemical agents can 
change these patterns over time7. DNA methylation plays a crucial role in 
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regulating several important factors in genome stability, X-chromosome 
inactivation, suppression of retrotransposon elements8, mammalian 
development6 and the regulation of gene expression in a specific cell during 
the different phases of the cell cycle9.  Since DNA methylation is reversible, 
DNA methylation inhibitor drugs such as 5-azacytidine (5-azaC) and 5-aza-
2'-deoxycytidine (5-azadC), were tested as anticancer drugs with the idea that 
such agents would demethylate and reactivate tumor suppressor genes. 
However, these agents might cause activation of a group of prometastatic 
genes in addition to activating tumor suppressor genes, which might lead to 
increased metastasis10. 
 
 
 
 
  
 
Figure 1: Model showing the inclusion of methyl group (CH3) on 5’ carbon of 
cytosine in CpG dinucleotide context. Modified figure from 11 
 
DNA demethylation 
The first discovery of methylcytosine  (5mC )12 was thought to be a stable 
epigenetic mark until the discovery of hydroxymethylation (5hmC) in mouse 
and human brains13. DNA methylation is a stable epigenetic mark which can 
only be reversed by inhibiting the maintenance enzyme during cell divisions 
(passive DNA demethylation), DNA methylation can be reversed in an active 
manner through the consecutive oxidation reactions (active DNA 
demethylation). With the help of DNMTs, cytosine is converted into 
methylcytosine. DNMT3A/B are the most important regulators for de novo 
methylation in early development processes, whereas DNMT1 maintains 
DNA methylation patterns through successive rounds of cell division14. Once 
established, the global DNA methylation patterns must be stably maintained 
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in order to ensure that transposons remain in a silenced state and to preserve 
cell-type identity. DNMT1 is associated with replication foci and functions to 
restore hemimethylated DNA generated during DNA replication to the fully 
methylated state15.   
Oxidation of DNA has traditionally been considered a DNA damage event, 
which is readily removed by DNA repair pathways. It has been well 
demonstrated that enzymatic oxidation of 5mC to 5hmC by TET proteins 
may act as a stable modification of DNA and downstream removal of 5hmC 
may actually be part of a complex and intricate process of epigenetic gene 
regulation. TET proteins are 2-oxoglutarate (2OG) - and Fe (II)-dependent 
enzymes that catalyzes 5mC into 5hmC, 5formylcytosine (5fC), 
5carboxylcytosine (5caC) by three consecutive oxidative reactions16. 
    Figure 2: DNA demethylation dynamics. Modified figure from17-19 
Further 5fC and 5caC are recognized by TDG proteins which activate the 
base excision repair pathway. There might be other proposed mechanisms for 
active DNA demethylation by enzymes like activation-induced deaminase 
(AID) which deaminates 5hmC, or Gadd45a to 5hmU, but this is still subject 
of debate20 (Figure 2).  
DNA methylation and Cancer  
Proper establishment and maintenance of DNA methylation patterns are 
essential for both embryonic developments and for the normal functioning of 
the adult organism. DNA methylation is a potent mechanism for silencing 
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gene expression and maintaining genome stability in the face of a vast 
quantity of repetitive DNA, which can otherwise mediate irregular 
recombination events and cause transcriptional deregulation of nearby genes 
causing various disorders including cancer, imprinting disorders, fragile X 
syndrome, immunodeficiency, centromeric instability and facial anomalies  
syndrome3,  Alzheimer’s disease21 and cardiovascular diseases22.  
One of the hallmarks of cancer is DNA methylation deregulation associated 
with global changes in gene expression levels. In a normal cell, DNA 
methylation occurs predominantly in repetitive genomic regions, including 
satellite DNA and parasitic elements (such as long interspersed transposable 
elements (LINEs), short interspersed transposable elements (SINEs) and 
endogenous retroviruses)23 and the methylation at individual CpG sites 
(mCpG) is established in a regional-specific manner, with some regions that 
remain unmethylated and others that are hypermethylated. In a cancer cell, 
this established methylation pattern is drastically modified, with some DNA 
regions undergoing methylation resulting in hypomethylated areas and some 
DNA regions undergoing de novo methylation resulting in hypermethylated 
areas. In a cancer cell, hypomethylation is linked with DNA instability and 
gene activation, whereas gene silencing and gene mutation are linked with 
hypermethylation in a cancer cell11 (Figure 3). Along with abnormal DNA 
methylation patterns in cancer, recent studies has highlighted on mutations 
that encounter genes the products of which are involved in epigenetic 
regulators such as DNA methyltransferases,  DNA demethylases, histone 
methyl- and acetyltransferases and in histone H3. Cytosines within CpG 
islands, especially those associated with promoter regions are less methylated 
in normal cells and lack of methylation in promoter-associated CpG islands 
allows gene transcription to occur, facilitating the binding of appropriate 
transcription factors maintaining open chromatin structure24.  The first-
observed epigenetic change in human cancer was a loss of DNA methylation 
throughout the genome were compared with a wide variety of normal 
tissues25. Seemingly, cancer cells are associated with global hypomethylation 
but with regional hypermethylation of CpG islands at gene promoters26. 
Abnormal genome-wide hypomethylation may relate to tumorigenesis by 
promoting genomic instability. DNA methylation of promoter CpG islands is 
associated with a closed chromatin structure and transcriptional silencing of 
the associated gene24,27. Loss of methylation may contribute to tumorigenesis 
in several ways including loss of imprinting28, generation of chromosomal 
Epigenetic regulation of oncogenes and tumor suppressors in chronic lymphocytic leukemia 
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instability29 and reactivation of normally methylated oncogenes30.  In chronic 
lymphocytic leukemia (CLL), based on genome-wide DNA methylation 
studies, hypomethylation occurred more frequently in gene body including 
introns, exons, and 3'-UTRs31.  
 
 
 
 
 
 
 
 
Figure 3: Model showing global DNA methylation status in normal and a cancer cell. 
Modified Figure from 11 
 
 
1.1.2  Histone modifications 
The size of DNA in a human diploid cell is approximately 2 meters (6 feet) if 
stretched. Interestingly, this long DNA is compacted and condensed in the 
nucleus of each cell with the help of histone proteins. Histones are small 
proteins with a positive charge, the main types of histones involved in 
compacting DNA are H1, H2A, H2B, H3, and H4; however, there are histone 
variants as well which have their own functions. Given that histones carrying 
net positive charges, DNA whose backbone is negatively charge is wrapped 
nearly twice around histones. 
Histones have protruding N-terminal tails which post-translationally can 
undergo chemical modifications known as histone modifications/marks. 
Histone modifications (depending on the residue they occur on, the type of 
modifications, and the number of modifications) are associated with the 
active or repressed state of genes32. Indeed, certain histone modifications can 
be used to predict gene expression33.  Several histone modifications are 
described, including acetylation, methylation, ubiquitination, phosphorylation 
and sumoylation34.   
mCpG
Normal Cell Cancer Cell
Hypermethylation Hypomethylation
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1.1.3  Nucleosome remodeling and chromatin modifiers 
The nucleosome is the fundamental unit of chromatin composed of 150bp of 
DNA wrapped into histone proteins35. Chromatin presents a significant 
barrier to the interaction of trans-acting factors with DNA in majority of 
cases where chromatin regulates many biological processes such as DNA 
replication, transcription, DNA repair, and DNA recombination. Histone 
modifications are added and removed by a group of enzymes that work in 
coordination with chromatin remodelers36. Nucleosome remodeling and the 
incorporation of histone variants are mediated by the action of ATP-
dependent chromatin remodeling complexes37,38. Chromatin 
remodeling complexes major function is to control gene expression by 
allowing access of condensed genomic DNA to the regulatory transcription 
machinery proteins39,40 
The Polycomb Group of proteins (PcG) form complexes that modify the 
chromatin, maintaining gene repression during development and 
differentiation. Polycomb Repressive Complex 1 and 2 (PRC1 and PRC2) are 
part of the polycomb group of protein complex.  Enhancer of zeste 
homologue 2 (EZH2) is one of the core members of the PRC2 complex 
involved in catalyzing silencing histone mark, which is H3K27me3. For 
certain genes, EZH2 mediated repression and DNA methylation are 
coordinated in order to maintain gene silencing. However, EZH2 can also 
directly control DNA methylation by recruiting DNA methyltransferases onto 
the target genes41, moreover, genes marked by PRC2-EZH2 are major targets 
for DNA methyltransferases. Many studies suggest that EZH2 acts as an 
oncogene and is aberrantly overexpressed in several types of cancer including 
in several hematological malignancies42-44.  
1.1.4   Non-coding RNAs mediated regulation 
The other epigenetic modifiers include non-coding RNA mediated gene 
silencing (ncRNAs). Misregulations of these RNAs are involved in many 
biological processes and have gained increasing importance in the past few 
years. ncRNAs are usually classified based on their mature length, location 
and orientation according to the nearest protein-coding gene, and their 
function which could be either cis or trans. The functional non-coding RNAs 
may include ribosomal RNA, transfer RNA, microRNAs (miRNAs, ~19-24 
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nucleotides), or long-noncoding RNAs (lncRNAs, > 200 nucleotides)45. Since 
my work is mainly involved in microRNA gene regulation; I would elaborate 
more on this particular class of small non-coding RNAs.  
 
MicroRNAs 
The first miRNA family lin-4  was identified in C. elegans through a genetic 
screen for defects in the temporal control of post-embryonic development46.  
MicroRNAs (miRNAs) are class of small (~19-24 nucleotides) non-coding 
RNAs which are highly conserved among mammals that guide post-
transcriptional repression of mRNA targets47,48. miRNAs play crucial roles in 
cell differentiation, proliferation, apoptosis, tumorigenesis and host-pathogen 
interactions49-51.  
In humans, miRNA sequences are located within various genomic contexts: 
the majority of canonical miRNAs are encoded by introns of coding or 
noncoding transcripts, but some miRNAs are encoded by exonic regions. 
Often, several miRNA loci are in close proximity to each other, constituting a 
polycistronic transcription unit52. The miRNAs in the same cluster are 
generally co-transcribed, but the individual miRNAs can be additionally 
regulated at the posttranscriptional level. Nearly the same fraction are hosted 
within and co-transcribed as part of a protein-coding messenger RNA 
(mRNA) transcription unit (TU). Classically, in the nucleus, these primary 
miRNA (pri-miRNA) are initially clipped out of the nascent TU by the 
microprocessor complex [DROSHA (RNase III enzyme) and DGCR8]. 
DGCR8 is believed to bind to a single-stranded portion of the pri-miRNA 
located at the base of the double-stranded stem, opposite the loop. Guided by 
DGCR8, DROSHA cleaves the pri-miRNA ~11 nucleotides (nt) into the 
stem, releasing a precursor miRNA (pre-miRNA) hairpin product comprised 
of the stem and loop53. Primary miRNA and RNA splicing processing 
appears to be tightly coordinated in the case of intron-resident miRNAs, with 
evidence pointing to miRNA “cropping” proceeding intron removal. The 
resulted pre-miRNA intermediate is shuttled out of the nucleus through the 
Exportin-5 nuclear transport receptor in cooperation with a Ran GTPase 
cofactor54. In the cytoplasm, the pre-miRNA is cleaved by Dicer, another 
RNase III-like enzyme, which generates mature miRNAs that ranges from 
~19-25nt with 2-??????????? ??? ?????????? ??? ????? ????? ???????? ??.Various 
transcription factors such as p53, MYC, ZEB1 and ZEB2 and myoblast 
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determination protein 1 (MYOD1) as well as epigenetic regulators positively 
or negatively regulate miRNA expression55.  
 
Figure 4: Model showing the biogenesis and post-transcriptional suppression of microRNAs. 
Modified figure from56,57  
Alteration of microRNA expression profiles occurs in most cancers, as 
approximately half of human microRNAs are located at fragile sites and 
genomic regions involved in alterations in cancers, suggesting that individual 
microRNAs could function as tumor suppressors58 or oncogenes59. Many 
recent studies have shown frequent deregulation of miRNAs occurs in 
various human malignancies including various leukemia59-66, 
lymphomas47,67,68. miR26A1 is a known tumor suppressor microRNA shown 
to be involved in pathways such as p53 and TGF beta pathways regulating 
several transformation-related targets, like SMAD169 and EZH270. 
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1.2   B-cell Malignancies  
Mature B-cell malignancies represent heterogeneous group of diseases with 
distinct genetic, phenotypical and clinical features. It is known that various 
lymphomas and leukemia occurs when the regulation of B-cell differentiation 
and activation is altered. These include follicular lymphoma, Burkitt 
lymphoma, multiple myeloma, diffuse large B-cell lymphoma, marginal zone 
lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia71,72. 
This thesis is mainly focused on chronic lymphocytic leukemia (CLL) and 
mantle cell lymphoma (MCL), both belonging to B-cell malignancies, but in 
many ways represents extremes within the spectrum of B-cell lymphomas. 
More detailed information on these two malignancies are described below.  
 
In order to know the classification and pathogenesis of CLL and MCL, 
sufficient knowledge on developmental stages of their counterparts is 
warranted. B-cells and T-cells arise from the hematopoietic (lymphoid) stem 
cell which is crucial to the human body’s ability to protect against infection 
and cancer by producing antibodies that attack pathogens and removing 
infected cells. B-cells play a pivotal role in clearing and preventing infection 
as well as offering protection against antigens73. Autoimmunity, malignancy, 
immunodeficiencies and allergy commonly occurs due to defects in B-cell 
development, selection and function74.  
In mammals, B lymphopoiesis takes place in the bone marrow (BM) from 
hematopoietic precursor cells, which depends on the interaction of stromal 
cells and growth factors, where they undergo VDJ rearrangement of the 
variable region of their immunoglobulin genes and start to express surface 
immunoglobulin (sIg)75. V-D-J rearrangement takes place at the first B-cell 
subset called the pro-B-cell. At this stage, CD19 is expressed and the IG 
heavy chain (IGH) chain locus starts to rearrange. Following this the pro-B-
cell becomes a pre B-cell and expresses the μ heavy chain on its surface. The 
pre–B-cells undergo 1 or 2 cell divisions and rearrange the gene segments 
encoding the k a????????????????????????????????????????????????????????
the cell surface when combined with the μ chain and these cells are termed 
immature B-cells76. The immature B-cells leave the BM and migrate to the 
periphery blood as so-called mature B-cells.  Mature B cells circulate in the 
periphery for few days or weeks and die if they do not encounter an antigen. 
These mature B-cells are called naïve B-cells co-express IgD and IgM and 
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start to circulate and recognize foreign antigens (Figure 5). This naïve B cell 
enters the lymphoid organs after the encounter with antigen and is activated 
in the outer T cell zone. Then the B cell can either becomes a plasma cell, 
secreting antibodies or enters primary follicles where it participates in giving 
rise to germinal centers (GCs)76,77. There are two zones in the GC called the 
dark and light zone in which the B cell differentiation and selection takes 
place78.  
 
 
Figure 5: Different stages of B-cell development 
 
During B-cell development, rearrangement of genetic segments of IGH gene 
loci which encodes the heavy chain of immunoglobulin takes place. The term 
immunoglobulin was proposed by Herman in 1959 for those globulins 
primarily associated with the lymphoreticular system79. Immunoglobulin 
consists of two heavy chains (IGH) and two light chains (IGL) which are 
linked together by disulfide bridges near the carboxy-terminal grouping of 
the light chain80 (Figure 6). Each component chain contains one NH2-
terminal variable (V) domain and one or more COOH-terminal constant 
domain (C). The three distinct gene segments which encode the heavy chain 
of the variable region includes variable (VH), diversity (D) and the joining 
region (JH) genes, whereas two segments-variable (VK or V?) and joining (JK 
or J?) region genes-encode the light chains
81,82. The IGH gene locus is located 
???????????????????????????????????????????????????????????????????????
on chromosome 2 and 22, respectively83,84. Each V gene segment typically 
contains its own promoter, a leader exon, an intron, an exon that encodes the 
four framework regions (FRs 1, 2, 3 and 4), complementarity-determining 
Stem cell        Pro B-cell         Pre B-cell      Immature B-cell      Naïve B-cell
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regions (CDRs) (CDR1, 2 and 3) and a recombination signal sequence (RSS). 
Each joining (J) gene segment begins with its own recombination signal, the 
carboxy-terminal portion of CDR3, and the complete. The initial event during 
IGH gene rearrangement juxtaposes a D region segment to a JH segment. 
After successful IGH- DJ recombination, a VH region gene rearranges to the 
D–JH complex as IGHV. The heavy chain C region remains separated from 
the rearranged IGHV-DJ complex by an intron, and this entire sequence is 
transcribed. After the productive rearrangement of at least one heavy chain 
gene, transcription of the rearranged locus occurs. μ heavy chain protein is 
expressed on the surface of pre-B-cells after translation85. These total gene 
recombination processes depend on the activity of enzymes. The creation of a 
V domain is directed by the RSSs that flank the rearranging gene segments 
which are dependent on the protein products of the recombinase activating 
genes (RAG-l and RAG-2)86-88. Both RAG1 and RAG2 introduce a DNA 
double-strand break between the terminus of the rearranging gene segment 
and its adjacent RSS and then these breaks are repaired by DNA repair 
process known as non-homologous end joining (NHEJ). Terminal 
deoxynucleotidyl transferase (TdT) one of the nuclear enzymes can variably 
add non–germline encoded nucleotides to the coding ends of the 
recombination product providing junctional diversity89. 
 
 
 
 
 
 
 
 
          Figure 6: Structure of immunoglobulin.  Modified figure from90-92 
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If one of the heavy chains in IGH rearrangements is unsuccessful during B-
cell development, recombination will initiate at the second one and if 
productive, these cells will then mature into pre-B-cells. If this rearrangement 
also fails, cells will undergo apoptosis85,93. 
1.2.1   Chronic lymphocytic leukemia 
CLL is the most common adult leukemia in western countries with approx. 
550 new patients diagnosed annually in Sweden94 and it is estimated that 
CLL will account for 20,110 new cases and 4,660 deaths in the US alone in 
201795.  
CLL is characterized by the accumulation of mature B lymphocytes 
specifically by the clonal expansion of CD5+ CD23+ in blood, bone marrow 
and secondary lymphoid tissues96,97.  CLL is most frequent in elderly people 
over the age of 60 with a median age 65 years and the incidence rate in men 
are twice as high as in women98-100. The incidence rates with people of 
African-Caribbean descent and Asian-Pacific show lower incidence than 
American-Europe descents. The reason behind this is still elusive but may 
reflect a combination of genetic and environmental factors101. Most CLL 
patients are often asymptomatic, commonly diagnosed in routine or other 
medical check-up and symptoms in advance disease include fatigue, fever, 
enlargement of lymph node, anemia, leukopenia, weight loss, night sweats 
and bone marrow failure100. The preliminary diagnosis is done in the presence 
??? ?? ????? ?-cells/microliter of peripheral blood for more than 3months102 
followed by  immunophenotyping: the composite immunophenotype CD5+, 
CD19+, CD20+ (low), CD23+, sIg low, CD79b low, FMC7– allows the 
distinction of most cases of B-cell type CLL from other CD5+ B-cell 
lymphoma103-105.  
1.2.1.1   CLL cell of origin 
CLL is classified into two prognostic groups based on the presence or 
absence of somatic hypermutations in the IGHV genes namely IGHV mutated 
(indolent and good survival rate) and IGHV unmutated (aggressive and poor 
prognosis)106,107.  Based on the observation that CLL cells carry either IGHV 
mutated or unmutated, it is proposed that M-CLL and UM-CLL cells are 
derived from two distinct populations: IGHV M-CLL cells are derived from 
the antigen-experienced post-germinal center B-cells, in the presence of T 
cell help. In contrast, IGHV UM-CLL is pre-GC derived from marginal zone 
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B-cells by T-cell independent processes106. However, evidence from gene 
expression profiling on CLL cells found that both IGHV mutated and 
unmutated cells share a common gene-expression profile suggesting they 
have a common origin and have a similar phenotype bearing markers of 
memory B-cells108,109. While there is no clear information the phenotype of 
the B-cells that clonally expands to generate CLL, evidence from recent 
studies suggests that the earliest genetic and epigenetic alterations leading to 
CLL may actually occur in pluripotent hematopoietic stem cells110 (Figure 7). 
In vivo experiments show that in mice injected with purified patient CLL-
HSCs but not CLL-pro or mature CLL can engraft efficiently into 
immunodeficient mice and cause the generation of CD19+ CD5+ CLL like 
B-cell clones with IGHV-DJ combinations.  
 
          Figure 7: The cellular origin of CLL. Modified figure from97,99   
Along with these, CLL-associated genetic lesions have been found in 
multipotent progenitors from patients with CLL, stating that the cellular 
origin of CLL occurs in a stepwise pattern that is initiated at a much earlier 
stage. Aberrations in HSC with predispositions for B-cell ontogenesis are 
suggested leading to polyclonal expansion at the pro-B-cell stage, and then to 
oligoclonal CD5+, monoclonal B-cell lymphocytosis (MBL), with each step 
leading to the acquisition of new malignant properties. Based on Kikushige et 
al’s model, progression from MBL to CLL requires further oncogenic events. 
IGHV mutated CLL seem to originate from post-GC CD5+ CD27+ B-cells 
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that have undergone GC reaction, whereas IGHV unmutated CLL seem to 
originate from pre-GC CD5+CD27- B-cells which may derive from the 
separate lineage of precursor B-cells or naïve B-cells97,110,111. 
 
1.2.1.2   Prognostic markers 
According to recent studies, the median survival of CLL patient was about 6 
years or more, although individual survival varies based on various 
factors112,113. Currently, there has been enormous progress in the 
identification and characterization of molecular and cellular markers that may 
predict the tendency of disease progression or detect minimal residual disease 
after therapy in CLL patients.   
 
Clinical staging  
So far the two widely used clinical staging systems which are recommended 
by the international workshop102 on CLL are Rai (0-IV)114 and Binet (A-C)115. 
Patients with Rai 0/ Binet A normally survive more than 10 years, Rai 
I/II/Binet B survive 5-?? ?????? ?????? ???? ????????????? ?? ???????? ?? ????????
These staging systems are based on the clinical characteristics of patients 
with CLL116,117. However, these staging systems fail to predict the higher risk 
of progression among patients in early stages of the disease and also 
identifying the prognostic subgroups and response to therapy118.  
 
Chromosomal aberrations 
All patients with CLL do not have a single cytogenetic defect.   Today with 
the use of fluorescence in situ hybridization (FISH) more than 80% of 
patients with CLL show one or more cytogenetic aberrations. The most 
common chromosomal aberrations include deletion of 13q14, trisomy 12, 
deletion of 11q22–23 and deletion of 17p13 (Table 1). In 2000, Dohner et al 
showed the survival analysis with various chromosomal aberrations based on 
FISH analyses of 325 CLL patients. A total of five different categories were 
defined: 17p deletion, 11q deletion, 12q trisomy, normal karyotype and 13q 
deletion as the single abnormality where the median overall survival was 32, 
79, 114, 111 and 133 months respectively and median treatment-free survival 
ranges between 9 and 92 months119 (Figure 8). According to multivariate 
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analysis, deletions of 11q22-q23 and 17p13, resulting in abnormalities of 
ATM (ataxia-telangiectasia mutated) and TP53 (encodes a tumor suppressor 
protein p53) genes, respectively, are independent prognostic factors 
identifying patients with a rapid disease progression with a poor overall 
survival. Deletion 11q patients tend to have an advanced clinical stage and 
lymphadenopathy. Deletion of 13q14 is associated with a good prognosis 
while trisomy 12 has an intermediate overall survival. Moreover, the 
deletions of 11q and 17p are frequently detected among the patients with 
unmutated IGHV genes at an advance stage of disease120-122. Interestingly, 
even though TP53 is located on 17p, there is no direct relation between them. 
In a study, patients having deletion 17p did not found TP53 while some 
patients having p53 mutation do not have a 17p deletion. In both cases, the 
CLL outcome showed poorer survival similar to carrying both 17 deletion 
and p53 mutation, suggesting the importance of p53 act as independent 
prognostic marker123. Patients with deletion 13q14 with higher frequency 
have a good prognosis, with survival curves that are even better than those 
with a normal karyotype. Two micro-RNA genes, namely miR15 and miR16 
at 13q14, are absent or down-regulated in most cases of CLL. miR15 and 16 
have been shown to target BCL-2 as part of the normal control of gene 
expression, and their absence in CLL appears to be a major factor in 
preventing apoptosis122,124,125. These major cytogenetic abnormalities have 
been used as prognostic categories for the most relevant risk estimation in 
patients with CLL.  
 
           Table 1: The major chromosomal aberrations in CLL 
Chromosome Genes involved Frequency (%) Category 
Del 13q14.3 miR15, miR16,  >50 Low risk 
Del 11q22-q23 ATM 19 High risk 
Trisomy 12 MDM-2 15 Intermediate risk 
Del 17p13.3 p53 15 Very high risk 
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Figure 8: Overall Survival from the Date of Diagnosis among the Patients based on five 
Chromosomal aberrations. Reproduced with permission from119, Copyright Massachusetts 
Medical Society. 
IGHV gene mutational status 
In 1999, two independent groups, namely Damle et al and Hamblin et al, 
reported that CLL patients can be divided into two prognostic subtypes based 
on the degree of somatic hypermutation and percentage of homology with 
IGHV gene sequence107,126. Patients with greater than 98% homology with 
IGHV gene sequence were designated as IGHV unmutated (with a median 
survival of 8 years from diagnosis), while patients with 98% or less 
homology with IGHV gene sequence were designated as IGHV mutated (with 
a median survival of 25 years). Patients with IGHV unmutated genes tend to 
have a more aggressive malignant condition, including adverse cytogenetic 
features (i.e., deletion 11q, deletion 17p), clonal evolution, resistance to 
therapy and poorer survival than those with mutated IGHV genes (Figure 9). 
IGHV mutations are independent with cytogenetic aberrations and clinical 
stages regarding prognostic significance particularly in patients with early-
stage disease127. However, exceptions do exist and that is the expression of 
the IGHV3-21 gene, which is associated with a poorer outcome 
independently of the IGHV mutational status128. Today, although many 
investigators believe that the mutation status of the IGHV genes is the best 
predictor of outcome, on a practical level, sequencing the IGHV is labor-
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intensive,  time-consuming and expensive which led to research efforts to 
identify surrogates for the mutational status, specifically CD38 and ZAP-70. 
 
 
 
 
 
 
 
 
Figure 9:  Comparison between IGHV mutated and unmutated prognostic subgroups. 
Modified  from 99 
 
Prognostic markers based on gene expression 
CD38 
CD38 is transmembrane glycoprotein which is 45kDa in humans which 
expresses at the cell membrane in high levels by B lineage progenitors in 
BM, B lymphocytes in the germinal center, activated tonsils, and by 
terminally differentiated plasma cells129,130. CD38 is also found in different 
areas of the brain, pancreatic acinar cells, smooth muscle cells, osteoclasts, 
although in most of these instances, CD38 is located in the cytosol and/or in 
the nucleus but not on the cell membrane130. CD38 plays a vital role in cell 
adhesion, calcium flux into the cell, proliferation and also influences B-cell 
apoptosis through BCR signaling131-133. Low levels of CD38 express in 
mature and memory B-cells. Damle et al, was the first group in CLL to show 
that expression of CD38 correlates with an aggressive mutation status107 and 
this was confirmed by subsequent studies134,135. CD38 expression as a 
prognostic factor on its own has also been shown to have unfavorable clinical 
outcomes with a decreased response to chemotherapy, shorter time to 
initiation of first treatment and decreased survival135. CD38 acts as an 
independent prognostic marker but is not the strongest marker due to its 
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limitation regarding the appropriate threshold to define CD38 positivity (5%, 
7%, 20% and 30%)118,136 and its expression change over the disease 
course137,138.  Lately, various studies have shown CD49d, a protein that 
mediates cell-cell interaction in CLL also co-expressed on CLL cells proving 
that prognostic value of this marker139,140.  
 
ZAP-70 
Zeta-chain-associated protein kinase 70 (ZAP-70), a 70-kDa T-cell receptor-
chain associated protein tyrosine kinase is the best surrogate marker for 
IGHV mutation status.  ZAP-70 higher expression is observed in normal NK 
and T cells, while the expression on normal B-cells is low or absent. In a 
study, Rosenwald et al. found that a small number of genes allow separating 
mutated and unmutated CLL, encoding most of the genes with ZAP-70. The 
majority of IGHV mutated cases are ZAP-70 negative, while unmutated cases 
are ZAP-70 positive108. In 2003, Wiestner et al and Crespo et al showed that 
the expression of ZAP-70 in CLL has correlated well with IGHV mutation 
(unmutated IGHV genes), disease progression and survival and also the 
expression of ZAP-70 showed to be quite stable over the course of the 
disease141,142  which was confirmed by subsequent sequential studies143-145. In 
another study, IGHV unmutated CLL cases with high ZAP-70 expression 
were frequently present with other cytogenetic features conveying poor 
prognoses such as deletion 17p, 11q or V3-21 expression146. ZAP-70 by itself 
can be an independent prognostic marker and CLL patients who express both 
ZAP-70 and CD38 markers seem to be in a high-risk category, whereas the 
patients of these markers are negative have a good prognosis and discordant 
cases fall in an intermediate-risk category147,148. Also, ZAP-70 methylation 
was shown to be a significant prognostic indicator for CLL where low ZAP-
70 methylation had significantly shortened time to first treatment and overall 
survival149.   
 
Methylation and gene expression correlating prognostic markers 
in CLL 
ANGPT2  
ANGPT2 (Angiopoietin 2), which plays an important role in angiogenesis is 
mainly secreted by endothelial cells at sites of active remodeling in an 
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autocrine manner150. ANGPT2 is elevated in many solid tumors and 
hematological malignancies while correlating with poor prognosis151-154. In 
CLL, the prognostic importance of ANGPT2 is well studied both on 
expression and methylation, in which high expression levels were found to be 
correlated with poor prognosis, predicting a shorter overall and first treatment 
survival. Both 24K and 450K genome-wide methylation array studies 
implicated ANGPT2 as one of the most significantly differentiated genes 
between IGHV prognostic subgroups155,156. ANGPT2 methylation correlated 
inversely with its mRNA expression levels and low ANGPT2 methylation 
status was associated with adverse prognostic markers and shorter overall 
survival157 suggesting ANGPT2 methylation also to be a good prognostic 
marker. 
 
LPL 
Lipoprotein lipase (LPL) has a pivotal role in lipid metabolism by catalyzing 
the hydrolysis of chylomicrons and very-low-density lipoproteins and also 
acts as a bridging protein between cell surface proteins and 
lipoproteins158.The expression of LPL in CLL B-cells has been related to 
fatty acid degradation and signaling functional pathways, which may 
influence CLL biology and clinical outcome159. LPL was identified initially 
as one of the most differentially expressed genes reported in the gene 
expression profiling studies by Rosenwald and Klein108,109 suggesting it as an 
independent prognostic marker also based on other studies too160-162.  
Epigenetic mechanisms have shown that LDL expression is associated with 
DNA demethylation of the LPL gene in unmutated CLL cases and this 
expression is dependent on microenvironment signals163,164 suggesting LPL 
methylation itself acts as an independent prognostic marker in CLL.  
 
Numerous factors including characteristics of the patient (gender, age, 
performance status, co-morbidity), the disease (burden, kinetics and biology 
of the tumor) and as well as the sensitivity of the disease to treatment are to 
be considered for prognosis of a given patient based on complex 
relationships. 
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nervous system and respiratory tract during the progression of the disease. 
The genetic hallmark of this neoplasm is the t(11;14)(q13;q32) translocations 
which involves the Ig heavy chain locus and the BCL-1 oncogene leading to 
the overexpression of cyclin D1, which has an important pathogenic role, 
likely deregulating cell cycle control by overcoming the suppressor effect of 
retinoblastoma 1 (RB1) and the cell cycle inhibitor p2747,172.  
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2 SPECIFIC AIMS 
 
1. To study the functional role of MCPH1 in regulation of ANGPT2 in CLL    
(Paper I) 
2. To study the role of epigenetic silencing of miR26A1 and its effect on 
EZH2 expression in CLL and MCL (Paper II) 
3. To study the functional role of gene-body hypermethylation in gene 
activation using TET1 as a model system in CLL (Paper III) 
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3 PATIENTS AND METHODS 
My thesis research work has been performed on both patient samples and 
leukemic cell lines. More detailed materials and methods are provided in the 
attached papers; hereby the detailed method principles are discussed. 
 
3.1 Patient materials 
CLL patient samples used in all three studies were diagnosed according to 
recently revised iwCLL criteria102 and peripheral blood mononuclear cell 
(PBMC) from patients with more than 70% of leukemic cells were selected 
and collected for the study. The CLL patient samples were collected at the 
Sahlgrenska University Hospital, Sweden, from the biobank at Uppsala 
University Hospital, Sweden, and University Hospital, Brno, Czech 
Republic. Other than CLL patient samples, MCL patient samples were used 
in paper II. MCL patient samples were diagnosed according to the WHO 
classification173 and collected from the biobank at Karolinska University 
Hospital, Huddinge, Sweden and also from the  Department of Molecular 
Medicine, University of Pavia, Italy. The percentage of Ki-67 staining with a 
25% cutoff was used to classify MCL into high proliferation and low 
proliferation (LP). For normal healthy controls, CD19+ sorted B-cells were 
isolated from 6 age-matched healthy buffy coats (range: 62–75 years). 
 
3.2 Cell lines and culture conditions 
Multiple cell lines were used in these studies. Two CLL (HG3 & MEC1), 
two MCL (GRANTA519 & Z138) cell lines were used in all the three papers. 
One Burkitt lymphoma (RAMOS) in the paper I and one breast 
adenocarcinoma (MCF-7) in the paper I and III were also used. CLL and 
MCL cell lines were cultured in RPMI-1640 media in the presence of 10% 
fetal bovine serum, 1x penicillin/streptomycin and 100 mM and 200 mM L-
Glutamine respectively. The MCF-7 cell line was used for siRNA 
transfections, ChIP assays and EMSAs which were cultured in the presence 
of Dulbecco’s Modified Eagle media supplemented with 10% heat-
inactivated FBS and 1x penicillin-streptomycin.  
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3.3 Gene expression analysis by real-time quantitative PCR 
mRNA gene expression analysis was performed using real-time quantitative 
PCR (qPCR). In my studies, both SYBR green and TaqMan based qPCR 
were performed to analyze the gene expression in both cell lines and patient 
samples. The basic principle of qPCR includes at first total RNA is 
transcribed into complementary DNA (cDNA) with the help of an enzyme 
called reverse transcriptase enzyme. The resultant cDNA is then used as the 
template for the qPCR reaction for analyzing gene expression. Primers were 
designed by using Primer 3 software for SYBR green based qPCR assay, 
whereas custom labelled ready to use TaqMan primers were used for TaqMan 
based qPCR assay. ???? method used for analyzing the expression of a gene 
of interest and the differences in expression were calculated with the help of a 
control gene. 
3.4 Protein expression analysis by western blot 
In the publications, assessment of protein levels was performed by western 
blot assay. Western blotting is a biochemical technique used to identify 
specific proteins in a complex sample mixture which was first described in 
1979174. The basic principle in western blotting is that the proteins are 
separated by size using sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and then transferred to a membrane by 
electroblotting. The membrane is then treated with blocking solution (5% 
BSA in our study) and then probed sequentially with primary and secondary 
antibodies to detect proteins of interest.  In all the three papers, western 
blotting was performed with equal amount of total cell lysates and in some 
cases nuclear lysates using RIPA buffer with PI inhibitors were loaded into 
Bis-Tris gels and transferred to Hybond ECL membranes. The membranes 
were then treated with 5% BSA in TBS with the addition of 0.1% Triton X-
100. After blocking, the membranes were incubated with the appropriate 
primary and secondary antibodies, followed by washes with TBS containing 
0.05% Triton X-100. Blots were visualized with SuperSignal West Dura 
Extended Duration Substrate using the ChemiDoc XRSC instrument.  
 
3.5 Methylation analysis using with pyrosequencing  
Quantitative measurement of methylation was performed with 
pyrosequencing. The pyrosequencing technique is based on a sequencing-by-
synthesis principle175 in which a DNA segment (bisulfite converted DNA) is 
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amplified and the strand to serve as the pyrosequencing template is 
biotinylated. The biotinylated single-stranded PCR amplicon after 
denaturation is isolated and allowed to hybridize with a respective 
sequencing primer.  Four enzymes namely DNA polymerase, ATP 
sulfurylase, luciferase, and apyrase, as well as the adenosine 5' 
phosphosulfate (APS) and luciferin substrates are incubated with the single-
strand template and hybridized primer in order to precisely detect nucleic 
acid sequences during the synthesis. At first, DNA polymerase catalyzes the 
addition of four deoxyribonucleotide triphosphate (dNTP) to the sequencing 
primer if it is complementary to the base in the template strand. 
Pyrophosphate (PPi) releases after each incorporation event in a quantity 
equimolar to the amount of incorporated nucleotide. This PPi converts into 
ATP by ATP sulfurylase in the presence of APS at which the ATP drives the 
luciferase-mediated conversion of luciferin to oxyluciferin that generates 
visible light which is proportional to the amount of ATP consumed. This 
visible light produced by this reaction is seen as a peak in the pyrogram 
output. Following this, nucleotide-degrade enzyme, Apyrase, degrades 
continuously the unincorporated nucleotides and also ATP. This process is 
continued and eventually, the complementary DNA strand is built up and the 
sequence is determined from the signal in the pyrogram where the percentage 
of methylation is noted176,177.  
For analyzing methylation levels, at first, the genomic DNA was bisulfite 
converted. Three primers, namely forward, reverse (one among this primer 
was biotin labelled) and sequence sequencing primer is designed with the 
help of pyro mark assay design software. The bisulfite converted DNA was 
amplified with forward and reverse primers. The amplified PCR product was 
immobilized with streptavidin sepharose high-performance beads followed 
by annealing with sequencing primer. The analysis was then performed using 
the pyrosequencer instrument and the CpG site methylation percentage of 
methylation was calculated for all CpG sites in the target sequence. 
 
3.6 Electrophoretic mobility shift (EMSA) assay  
EMSA is a sensitive and rapid method to detect DNA binding proteins was 
developed as a method in 1981178.  In this technique, DNA-protein complexes 
migrate slower than non-bound DNA in a native polyacrylamide or agarose 
gel, resulting in a “shift” in the migration of the labelled DNA band179. Here 
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we used this method for the detection of transcription factors and other 
sequence-specific DNA binding proteins.   
In my first paper, we performed EMSA in which at first the nuclear extracts 
from siRNA-transfected MCF-7 cells and from the PBMCs of CLL patients 
were prepared. Equal amounts of nuclear extract protein were incubated with 
poly (dIdC), 32P-labeled oligonucleotide probe/biotin-labelled ANGPT2 
probe (with and without a possible MCPH1-binding site), and 1x binding 
buffer. Following this, the samples were incubated on ice, and run on 6% 
DNA retardation gels. Membranes were cross-linked with UV, blocked and 
conjugated followed by incubation of MCPH1 antibody. The radioactive gels 
were analyzed directly by phosphorimager analysis, and whereas biotin 
labelled gels were developed with an equipped CCD camera ChemiDoc 
XRSC instrument.   
 
3.7 Chromatin immunoprecipitation (ChIP) assay 
Chromatin immunoprecipitation (ChIP) is a well-known and common 
technique for investigating specific protein–DNA interactions and also 
become one of the most practical and useful techniques to study the 
mechanisms of gene expression, histone modification, and transcription 
regulation. The principle behind the ChIP assay included to fix the protein-
DNA complex in living cells and then randomly sheared into 100-500 bp 
DNA fragments by sonication or nuclease digestion methods to selectively 
enrich the DNA fragments fixed with targeted protein by using ChIP-grade 
antibodies followed by purification before using in downstream analysis180-
182. 
In the paper I and III, ChIP was performed on the transfected cells which 
were crosslinked with formaldehyde, lysed and sonicated four times for 
10min each. The sonicated complex was incubated with appropriate ChIP-
grade antibodies and purified. The final precipitated DNA was analyzed by 
SYBR green-based real-time quantitative PCR. ???? method from the Excel-
based ChIP-qPCR analysis template was used for the calculation of the 
normalized percentage of input and fold enrichment values for ChIP data. 
 
3.8 Measuring the promoter activity by Luciferase reporter assay 
Luciferase and ?-galactosidase assays were used to study gene expression as 
well as other cellular components and events that are involved in gene 
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regulation. This assay is extremely rapid, simple, sensitive, and possesses a 
broad linear range. Due to its high sensitivity, even small changes in 
transcription can be quantified. The principle of this luciferase reporter assay 
includes the use of luciferases which are oxidative enzymes that convert 
luciferin into oxyluciferin in the presence of oxygen by which the energy 
released measured in the form of visible light or bioluminescence. At first, 
the regulatory region of an interested gene cloned in the luciferase expression 
vectors which then introduce the resulted vector DNA transfected into cells 
and then allow the cells to grow over a period of time. The transfected cells 
were lysed and measured using a luminometer in the presence of luciferin 
and necessary cofactors. The resultant light from lysates gives quantitative 
reading by which the luciferase activity can be directly correlated the activity 
with the gene of interest183.  
Luciferein+O2+ATP                       Oxyluciferin+CO2+AMP+PPI+LIGHT 
 
In the paper I, MCPH1 and ANGPT2 promoters and in paper III, in order to 
identify the HMR promoter activity and downstream cryptic region, the 
sequences were cloned into a vector and PCR-amplified. These amplified 
promoter sequences were cloned into the respective basic Luciferase vector 
and transiently transfected into MCF-7 cells in the presence of a ?-
galactosidase reporter gene. Luciferase activity was determined 24 h and 48 h 
after transfection by use of the dual-luciferase reporter assay system in 
duplicate samples manually. The emitted relative light units were measured 
with a luminometer and the final luciferase values (relative light units) were 
calculated by dividing the luciferase activity by the ?-galactosidase activity.  
 
3.9 Analysis of protein-protein binding affinities by Co-
immunoprecipitation (Co-IP) 
Co-IP is widely used to study protein-protein binding affinities by using 
specific antibodies to indirectly capture proteins that are confining to a 
specific target protein.  In a co-IP, at first the antibody against a target protein 
is coupled to sepharose beads and the complexes containing the target protein 
are immunoprecipitated by centrifugation with antibody coupled beads. The 
targeted protein components in the complexes are visualized by western 
blotting using specific antibodies to the different components184.  
Luciferase 
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In Paper I, co-IPs have been performed to check the binding affinities of 
MCPH1, E2F1, DNMT1 and DNMT3b proteins by using sepharose G beads 
and followed western blotting to detect the specific binding affinities of these 
proteins.  
3.10 Assessment of apoptosis and expression through flow cytometry 
(FACS) 
Flow cytometry is a powerful tool that utilizes multiparametric laser-based-
technology to analyze the physical characteristics of single cells and count, 
sort and profile cells in a heterogeneous fluid mixture. FACS determines the 
phenotype, function and sorts the cells according to these parameters. The 
principle behind FACS include the cells or other substances suspended in a 
liquid stream mixture being passed through a laser beam one at a time, by 
which the interaction of the light is measured as light scatter and fluorescence 
intensity. The specific cellular component is bound to the defined 
fluorochrome by which the fluorescence intensity will ideally represent the 
amount of that specific cell component185,186. FACS analysis was performed 
in the paper II to measure apoptosis by Annexin V and EZH2 expression 
levels and data analyzed using the FACSDiva software. We followed the kit 
protocol for analyzing the apoptosis and to analyze the EZH2 expression 
levels. Cells were permeabilized with solution B followed by incubation with 
diluted EZH2 primary antibody and APC conjugated goat anti-rabbit IgG 
secondary antibody.   
 
3.11 Statistical analysis 
All statistical analyses were performed with SPSS, STATISTICA and 
GraphPad Prism software. In the paper I, correlations between MCPH1 
variants, ANGPT2 and hTERT were made and in paper II the correlation of 
expression levels of miR26A1 and EZH2 were assessed by Spearman’s two-
tailed correlation analysis.  All the comparisons between groups were 
performed with a two-tailed Student’s t-test in the papers. For the assessment 
of overall survival, the Kaplan–Meier survival analysis with a log-rank test 
was performed.  
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4 RESULTS & DISCUSSION 
4.1 MCPH1 maintains long-term epigenetic silencing of ANGPT2 
in chronic lymphocytic leukemia (Paper I) 
Microcephalin (MCPH1) is a well-known tumor suppressor, implicated in 
DNA damage response, cell cycle regulation, X-chromosome inactivation in 
development and chromosome condensation, and whereas ANGPT2 is an 
oncogene157 involved in angiogenesis and having a major role in tumor 
growth and metastasis. ANGPT2 is located on the same chromosome as 
MCPH1 and overlaps with MCPH1 in the opposite orientation. In this paper, 
we wanted to study the functional role of MCPH1 in regulating ANGPT2, 
along with hTERT which is a direct target of MCPH1. Both ANGPT2 and 
hTERT show differential expression and are regulated epigenetically by DNA 
promoter methylation. Although the prognostic importance of ANGPT2 and 
hTERT in CLL has been shown earlier, the prognostic value of MCPH1 in 
CLL subsets has not been studied previously. In this study, using Spearman 
correlation analysis, the expression level of MCPH1 was shown to be 
significantly inversely correlated with the expression of ANGPT2 and 
hTERT. The mRNA expression levels of MCPH1, ANGPT2 and hTERT 
showed statistically significant differences between CLL prognostic 
subgroups IGHV mutated and IGHV unmutated (MCPH1, P=0.007; 
ANGPT2, P=0.0002; hTERT, P<0.0001) based on the qPCR analysis. When 
MCPH1 was downregulated in CLL cell lines, we observed upregulation of 
ANGPT2, accompanied by loss of its promoter methylation, implicating the 
role of MCHP1 in ANGPT2 regulation. Here we showed mechanism behind 
MCPH1 mediated regulation of ANGPT2 promoter, either through  promoter 
competition model (as both promoters contain E2F1- binding sites and have 
been shown to be induced by increasing concentrations of E2F1) or silencing 
of the promoter in cis (as shown by MCPH1-mediated silencing of hTERT 
promoter activity by binding to its promoter).  Later, using ChIP assay and 
Co-IPs, we also noticed that MCPH1 binds to the ANGPT2 promoter and 
recruits DNA methyltransferases, thereby silencing ANGPT2 in IGHV 
mutated CLL samples where MCPH1 is expressed in higher levels compared 
to IGHV unmutated samples (Figure 11).  
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Figure 11: Model explaining the role of MCPH1 in regulating ANGPT2 expression in both 
IGHV-unmutated and IGHV-mutated CLL patient samples in vivo.  
 
 
According to our results, along with ANGPT2 and hTERT, the MCPH1 
expression could be a possible prognostic marker in CLL. MCPH1 has three 
variants namely MCPH1 full length, MCPH1 Sh1 and MCPH1 Sh2. Here, we 
studied the role of MCPH1 full length and Sh2 but not Sh1 as this variant has 
complete sequence homology which cannot be distinguished with other 
variants. In conclusion, we showed a novel function of MCPH1 in epigenetic 
silencing of the ANGPT2 promoter by interacting with and recruiting 
DNMTs to this promoter in CLL and with these results, our study unravels 
reason behind the differential methylation status of ANGPT2 in CLL.  
 
 
 
4.2 Epigenetic silencing of miR-26A1 in chronic lymphocytic 
leukemia and mantle cell lymphoma: Impact on EZH2 expression 
(Paper II) 
In line with earlier published studies, our study also reported downregulation 
of miR26A1 in CLL as shown in a variety of B-cell malignancies with lower 
expression levels in CLL patient samples compared to normal B-cells 
suggesting that miR26A1 acts as tumor suppressor microRNA47,155,187-189. On 
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the other hand, EZH2 which is shown to be overexpressed in CLL is known 
to silence gene promoter either directly using histone methyltransferase 
activity or through DNA methylation machinery. According to our earlier 
published 450K DNA methylation array data, miR26A1 was differentially 
hypermethylated between CLL prognostic groups. We also performed 450K 
methylation arrays in MCL patient samples and found that miR26A1 was 
significantly hypermethylated in all samples compared to normal healthy 
controls. To validate the findings of 450K DNA methylation array data in 
CLL and MCL, we investigated the molecular role of miR26A1 and also its 
target EZH2, using a large cohort of CLL and MCL samples. Based on our 
pyrosequencing and RT-PCR analysis, miR26A1 was hypermethylated and 
poorly expressed in CLL and MCL samples compared to normal healthy B-
cells suggesting that the above results clearly support with 450K DNA 
methylation array data. Moreover, the percentage of miR26A1 methylation 
predicts risk stratification in CLL, where hypermethylation correlates with 
poor prognosis and shorter survival. In order to investigate the functional role 
of miR26A1 in regulating its target EZH2, we have overexpressed miR26A1 
mimic microRNA and negative control mimic microRNA in CLL and MCL 
cell lines using Amaxa Nucleofection. Immunoblotting and FACS labelling 
showed reduced EZH2 protein levels in all cell lines. Furthermore, to know 
the correlation between miR26A1 and EZH2, we first selected CLL primary 
samples exhibiting very high (10 samples out of 70 samples) and low (10 
samples) expression levels in miR26A1 and analyzed the EZH2 mRNA 
expression levels using RT-PCR.  There was a significant negative 
correlation between miR26A1 and EZH2 (P=0.04, r= -0.45). Increased 
apoptosis was observed when miR26A1 was overexpressed in CLL and MCL 
cell lines, followed by a decrease in EZH2 protein levels which was analyzed 
by FACS. In CLL, the more varying degree of miR26A1 methylation was 
noted, with high methylation predicting a significantly shorter survival, a 
finding that needs further studies. Thus our data showed that miR26A1 was 
epigenetically regulated by DNA hypermethylation in CLL and MCL 
primary samples compared with normal samples. With these results, we 
conclude a tumor suppressor role of miR26A1 in CLL and MCL, which is 
regulated by DNA hypermethylation. Overall, with our results, we suggest 
that EZH2 could be one of the therapeutic targets in CLL.   
 
Pradeep Kumar Kopparapu 
33 
4.3 Gene-body hypermethylation controlled cryptic promoter and 
miR26A1-dependent EZH2 regulation of TET1 gene activity in 
chronic lymphocytic leukemia (Paper III)  
 
The Ten-eleven-translocation 1 (TET1) is differentially expressed in 
leukemia as in many other cancers. However, the mechanism behind TET1 
gene regulation is still not known. Gene-body hypermethylation studies 
recently point out a transcriptional regulatory step in controlling alternative 
splicing and cryptic promoter190,191. Earlier, using MBD seq192 for DNA 
methylation profiling between CLL patient samples and normal B-cell 
controls we found that TET1 was one of the significantly differentially 
methylated genes with gene-body hypermethylation. Here, we wanted to 
understand the role of gene-body hypermethylation in TET1 gene expression 
as gene-body hypermethylation was shown to be correlated with gene 
activation. We characterized the mechanisms that control TET1 gene activity 
at the transcriptional level by using both patient and cell line samples. We 
validated the expression and methylation status of TET1 using 40 CLL 
patient samples and two different CLL cell lines. Our data showed that there 
is a significant differential expression of TET1 in CLL compared with normal 
control samples which also supported the analysis performed by us with 
independently published RNA seq data193.  Our study showed that unlike 
promoter methylation, gene-body hypermethylation of TET1 positively 
correlated with TET1 gene expression in CLL samples. According to our 
earlier study in CLL58 miR26A1 was shown to be promoter hypermethylated 
and silenced, so we treated CLL cell lines with 5-aza-2'-deoxycytidine 
(DAC) which resulted in the activation of miR26A1 (which was shown to 
directly target EZH2), resulting in a decrease in both mRNA and protein 
levels of EZH2. Based on ChIP assays we noticed that miR26A1 can regulate 
TET1 at the transcriptional level through negatively correlating with EZH2 
expression levels, illustrating the functional interplay between EZH2, TET1 
and miR26A1. These further results in the decreased occupancy of EZH2 over 
the TET1 promoter and consequently exhibits the loss of TET1 expression. 
Moreover, we identified the presence of cryptic promoter on TET1 
hypermethylated gene-body based on both strand-specific RT-PCR and 
promoter luciferase assay, suggesting that cryptic promoter encodes antisense 
transcripts.  Furthermore, we found that antisense cryptic transcription may 
be regulating TET1 gene expression in part by occluding the transcription 
initiation machinery from the TET1 promoter. We showed a novel correlation 
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between increased expressions of intronic transcripts with decreased TET1 
promoter activity through the loss of RNA Pol II occupancy (Figure 12). 
Further studies are needed to characterize the functional role of the identified 
cryptic transcript in CLL.  
 
  
DAC     
 
 
 
Figure 12: Model explaining the role of DNA hypermethylation in regulating TET1 gene 
expression.  
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5 CONCLUSION 
My thesis is about understanding the epigenetic mechanisms involved in 
regulating tumor suppressors and oncogenes which are selected as 
significantly differentially methylated in CLL samples compared to normal 
healthy controls using global DNA methylation profiling studies. For the 
validation studies, independent large cohorts of CLL patient samples are used 
for the gene expression and methylation analysis. In addition to CLL samples 
to unravel the epigenetic mechanisms of these tumor suppressors and 
oncogenes, we used CLL and MCL cell lines as a model system. My work 
has shown the DNA methylation has a prominent role on regulating the gene 
expression in CLL and also the percentage of DNA methylation can be used 
as an independent prognostic marker along with existing markers such as 
CD38, ZAP70, IGHV mutational analysis etc.., which also correlates with 
overall survival in CLL patient samples.  
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